Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
83 Leser
Artikel bewerten:
(0)

EQS-News: Edison Investment Research Limited: Edison issues initiation on NeuroVive Pharmaceutical (NVP)

Dow Jones received a payment from EQS/DGAP to publish this press release.

EQS-News: Edison Investment Research Limited / Key word(s): Research Update 
Edison Investment Research Limited: Edison issues initiation on NeuroVive 
Pharmaceutical (NVP) 
 
29-Jun-2017 / 11:30 GMT/BST 
 
London, UK, 29 June 2017 
 
*Edison issues initiation on NeuroVive Pharmaceutical (NVP)* 
 
NeuroVive Pharmaceutical is a mitochondrial medicine specialist with a 
diversified asset portfolio. It employs a two-pronged strategy and has a 
portfolio of drug candidates for orphan mitochondrial diseases, which it 
aims to develop internally; more recently, it has also identified in-house 
assets suitable to tackle larger indications, which NeuroVive aims to 
out-license in pre-clinical development. The most advanced projects are 
Phase IIb ready NeuroSTAT for traumatic brain injury and KL1333 in Phase I 
for various mitochondrial diseases. We value NeuroVive at SEK1.5bn. 
 
We value NeuroVive at SEK1.5bn or SEK30/share based on a risk-adjusted NPV 
model using a 12.5% discount rate, including SEK67.3m net cash at end-Q117. 
We include five of the company's seven assets. We value the two clinical 
stage assets, NeuroSTAT and KL1333, at SEK299m and SEK441m respectively, 
which comprises 50% of the total rNPV. NeuroVive's initiation of the 
proof-of-concept Phase IIb trial with NeuroSTAT in TBI and initiation of the 
Phase I study with KL1333 by NeuroVive (Yungjin is already recruiting to its 
own Phase I) are the near-term R&D events within the next 12-18 months. 
Meanwhile, potential out-licensing of NV556 could be a substantial trigger 
for the share price. 
 
Click here [1] to view the full report. 
 
All reports published by Edison are available to download free of charge 
from its website 
www.edisoninvestmentresearch.com [2] 
 
*About Edison:* Edison is an investment research and advisory company, with 
offices in North America, Europe, the Middle East and AsiaPac. The heart of 
Edison is our world-renowned equity research platform and deep multi-sector 
expertise. At Edison Investment Research, our research is widely read by 
international investors, advisers and stakeholders. Edison Advisors 
leverages our core research platform to provide differentiated services 
including investor relations and strategic consulting. 
 
Edison is authorised and regulated by the Financial Conduct Authority [3]. 
 
Edison is not an adviser or broker-dealer and does not provide investment 
advice. Edison's reports are not solicitations to buy or sell any 
securities. 
 
*For more information please contact Edison:* 
 
Jonas Peciulis, +44 (0)20 3077 5728 
healthcare@edisongroup.com 
 
Learn more at www.edisongroup.com [4] and connect with Edison on: 
 
LinkedIn https://www.linkedin.com/company/edison-investment-research [5] 
 
Twitter www.twitter.com/Edison_Inv_Res [6] 
 
YouTube www.youtube.com/edisonitv [7] 
 
Dissemination of a UK FINANCIAL NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
587715 29-Jun-2017 
 
 
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=a16e8d0279a86152c851d447c5c02be5&application_id=587715&site_id=vwd&application_name=news 
2: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=e7266211cbf0b72f2b3d94ab8bdaae97&application_id=587715&site_id=vwd&application_name=news 
3: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=105fe9be9b5e36892886e5a39d51d4b7&application_id=587715&site_id=vwd&application_name=news 
4: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=88c95533002fab2316572f9ef6cf3cc6&application_id=587715&site_id=vwd&application_name=news 
5: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=edc5483da45ef361071849742dbf1595&application_id=587715&site_id=vwd&application_name=news 
6: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ec2d264fe4f303e2143a2e85c6eaa823&application_id=587715&site_id=vwd&application_name=news 
7: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=6b959e4d7ee3c402b931a274d2bbe945&application_id=587715&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

June 29, 2017 06:30 ET (10:30 GMT)

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2017 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.